tetano
Editor, Senior Moderator
Vaccine
. 2024 May 6:S0264-410X(24)00519-X.
doi: 10.1016/j.vaccine.2024.04.079. Online ahead of print. Intranasal immunization with the bivalent SARS-CoV-2 vaccine effectively protects mice from nasal infection and completely inhibits disease development
Tuksin Jearanaiwitayakul[SUP] 1 [/SUP], Panya Sunintaboon[SUP] 2 [/SUP], Anuwat Kittiayuwat[SUP] 3 [/SUP], Jitra Limthongkul[SUP] 3 [/SUP], Jidapar Wathanaphol[SUP] 3 [/SUP], Yada Janhirun[SUP] 4 [/SUP], Hatairat Lerdsamran[SUP] 5 [/SUP], Witthawat Wiriyarat[SUP] 6 [/SUP], Sukathida Ubol[SUP] 7 [/SUP]
Affiliations
With the continuous emergence of coronavirus disease 2019 (COVID-19) waves, the scientific community has developed a vaccine that offers broad-spectrum protection at virus-targeted organs for inhibiting the transmission and protection of disease development. In the present study, a bivalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine containing receptor-binding domain (RBD) protein of spike from Wuhan-1 and omicron BA.1 loaded in nanoparticles, bivalent RBD NPs, was developed. The immunogenicity and protective efficacy of this vaccine candidate were evaluated using an in vivo model. Results showed that mice that received intranasal cGAMP-adjuvanted bivalent RBD-NPs vaccine elicited robust and durable antibody responses. The stimulated antibody broadly neutralized the ancestral strain and variants of concerns (delta and omicron BA.1) in the upper and lower respiratory tracts. Furthermore, the immunized mice developed T-cell response in their lung tissue. Importantly, intranasal immunization with this vaccine candidate efficiently protected mice from nasal infection caused by both Wuhan-1 and BA.1 viruses. Immunized mice that remained susceptible to nasal infection did not develop any symptoms. This is because activated responses in the nasal cavity significantly suppressed virus production. Another word is this nasal vaccine completely protected the mice from disease development and mortality. Therefore, the bivalent RBD vaccine platform has potential to be developed into an anti-SARS-CoV-2 universal vaccine.
Keywords: Bivalent RBD vaccine; Intranasal vaccination; SARS-CoV-2; Vaccine effectiveness.
. 2024 May 6:S0264-410X(24)00519-X.
doi: 10.1016/j.vaccine.2024.04.079. Online ahead of print. Intranasal immunization with the bivalent SARS-CoV-2 vaccine effectively protects mice from nasal infection and completely inhibits disease development
Tuksin Jearanaiwitayakul[SUP] 1 [/SUP], Panya Sunintaboon[SUP] 2 [/SUP], Anuwat Kittiayuwat[SUP] 3 [/SUP], Jitra Limthongkul[SUP] 3 [/SUP], Jidapar Wathanaphol[SUP] 3 [/SUP], Yada Janhirun[SUP] 4 [/SUP], Hatairat Lerdsamran[SUP] 5 [/SUP], Witthawat Wiriyarat[SUP] 6 [/SUP], Sukathida Ubol[SUP] 7 [/SUP]
Affiliations
- PMID: 38714446
- DOI: 10.1016/j.vaccine.2024.04.079
With the continuous emergence of coronavirus disease 2019 (COVID-19) waves, the scientific community has developed a vaccine that offers broad-spectrum protection at virus-targeted organs for inhibiting the transmission and protection of disease development. In the present study, a bivalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine containing receptor-binding domain (RBD) protein of spike from Wuhan-1 and omicron BA.1 loaded in nanoparticles, bivalent RBD NPs, was developed. The immunogenicity and protective efficacy of this vaccine candidate were evaluated using an in vivo model. Results showed that mice that received intranasal cGAMP-adjuvanted bivalent RBD-NPs vaccine elicited robust and durable antibody responses. The stimulated antibody broadly neutralized the ancestral strain and variants of concerns (delta and omicron BA.1) in the upper and lower respiratory tracts. Furthermore, the immunized mice developed T-cell response in their lung tissue. Importantly, intranasal immunization with this vaccine candidate efficiently protected mice from nasal infection caused by both Wuhan-1 and BA.1 viruses. Immunized mice that remained susceptible to nasal infection did not develop any symptoms. This is because activated responses in the nasal cavity significantly suppressed virus production. Another word is this nasal vaccine completely protected the mice from disease development and mortality. Therefore, the bivalent RBD vaccine platform has potential to be developed into an anti-SARS-CoV-2 universal vaccine.
Keywords: Bivalent RBD vaccine; Intranasal vaccination; SARS-CoV-2; Vaccine effectiveness.